Rodrigues Anabela, Cabrita Antonio, Maia Pedro, Guimarães Serafim
Nephrology Department, Hospital Geral Santo Antonio, Porto, Portugal.
Adv Perit Dial. 2002;18:78-80.
Temporary transfer to hemodialysis, as a peritoneal rest, may be a rescue therapy to recover ultrafiltration (UF) in patients who develop peritoneal hyperpermeability as a complication of continuous ambulatory peritoneal dialysis (CAPD). However, peritoneal sclerosis has been reported after peritoneal pause. Since the beginning of our CAPD program in 1985, 12 elective peritoneal pauses have been performed in 11 patients who developed type I ultrafiltration failure (D/P240 creatinine: 0.88 +/- 0.09) after 42 +/- 14 months on CAPD. Eight patients recovered UF and remained on CAPD with standard solutions for 10 +/- 9 months more (minimum: 5 months; maximum: 29 months). Only 3 of those patients were later switched to hemodialysis because of recurring UF failure. One patient remains on CAPD (62 months of follow-up). Four patients failed to respond and were permanently transferred to hemodialysis, without signs of developing encapsulating peritoneal sclerosis. The failed pauses were performed later after the detection of UF failure than were the successful ones (483 +/- 574 days vs. 54 +/- 52 days). In our study, 8 of 12 peritoneal pauses (66.6%) successfully treated type I UF failure and prolonged CAPD retention. If a pause is initiated soon after diagnosis of UF failure, results may improve further. We urge prospective studies to better determine the best and timely therapeutic approach in patients with loss of ultrafiltration.
作为一种腹膜休息方式,临时转为血液透析可能是一种挽救疗法,用于恢复那些因持续非卧床腹膜透析(CAPD)并发症而出现腹膜高通透性的患者的超滤功能(UF)。然而,据报道腹膜暂停后会发生腹膜硬化。自1985年我们开展CAPD项目以来,11例患者在接受CAPD 42±14个月后出现I型超滤衰竭(D/P240肌酐:0.88±0.09),共进行了12次选择性腹膜暂停。8例患者恢复了超滤功能,并继续使用标准溶液进行CAPD治疗10±9个月(最短:5个月;最长:29个月)。其中只有3例患者后来因超滤衰竭复发而转为血液透析。1例患者仍在进行CAPD(随访62个月)。4例患者无反应,永久性转为血液透析,未出现包裹性腹膜硬化迹象。失败的腹膜暂停比成功的腹膜暂停在检测到超滤衰竭后进行得更晚(483±574天对54±52天)。在我们的研究中,12次腹膜暂停中有8次(66.6%)成功治疗了I型超滤衰竭并延长了CAPD保留时间。如果在诊断超滤衰竭后不久就开始暂停,结果可能会进一步改善。我们敦促进行前瞻性研究,以更好地确定超滤功能丧失患者的最佳和及时的治疗方法。